Voyager Acquisition Corp - Class A Ordinary Shares (VACH)

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH) announced a definitive agreement to merge in a transaction that would value the combined company at approximately $1.64 billion. Upon closing, VERAXA is expected to trade on NASDAQ under the ticker symbol “VERX.” The company is advancing a proprietary Bi-Targeted Antibody Cytotoxicity (“BiTAC”) platform for dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers, with a pipeline featuring nine programs and an active Phase 1 trial in leukemia. VERAXA is backed by majority shareholders Xlife Sciences AG (SIX: XLS), EMBL and EMBLEM, and led by CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA. Voyager expects to provide up to $253 million in cash from its trust account to fund operations, while VERAXA is pursuing a crossover round expected to close before the deal’s completion, targeted for Q4 2025.

Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies